TY-JOURA2-Cavaliere、CarloAU-Melgaço、JulianaGilAU-Britoe-E库尼亚、DanielleAU-Azamor、TamirisAU-da Silva、Andrea Marques VieaAU-Tubarão、LucianaNevesAU-Gonçalves、RafaelBragaAU-MonteiroAU - Missailidis, Sotiris AU - da Costa Neves, Patricia Cristina AU - Ano Bom, Ana Paula Dinis PY - 2020 DA - 2020/12/22 TI - Cellular and Molecular Immunology Approaches for the Development of Immunotherapies against the New Coronavirus (SARS-CoV-2): Challenges to Near-Future Breakthroughs SP - 8827670 VL - 2020 AB - The severe acute respiratory syndrome caused by the new coronavirus (SARS-CoV-2), termed COVID-19, has been highlighted as the most important infectious disease of our time, without a vaccine and treatment available until this moment, with a big impact on health systems worldwide, and with high mortality rates associated with respiratory viral disease.医学界和科学界还面临更好地了解宿主病毒交互机制的迫切需求,以开发治疗法和疫苗病毒性疾病可触发强生免疫响应,严重损害肺道,因此还探索免疫治疗方法,以验证免疫机能并改进临床结果,而综合COVID-19免疫学仍在调查中在这次审查中摘述细胞和分子免疫病理学以及SARS-COV-2诱发的超感性失序基于最新临床和非临床研究的免疫代谢方法也得到了处理,强调其对COVID-19处理的影响所介绍的信息说明帮助洞察力,以填补有希望免疫疗法知识空白,这些疗法试图控制宿主因素在这一传染病毒疾病过程中失灵SN-2314-8861UR-https://doi.org/101155/208827670DO-10.1155/208827670JF-Imunology研究PB-Hindawi KW-ER